(6-isopropyl-pyrimidin-4-yl)-methyl-amine | 52698-66-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (6-isopropyl-pyrimidin-4-yl)-methyl-amine
• 英文别名: 6-Isopropyl-N-methylpyrimidin-4-amine；N-methyl-6-propan-2-ylpyrimidin-4-amine
• CAS: 52698-66-5
• 化学式: C₈H₁₃N₃
• 分子量: 151.211
• InChiKey: RKACYQKAYVNEBY-UHFFFAOYSA-N

物化性质

• 沸点：
  260.7±28.0 °C(Predicted)
• 密度：
  1.039±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Bis-aryl urea compounds and methods of use
  申请人：Geuns-Meyer D. Stephanie

  公开号：US20070049592A1

  公开（公告）日：2007-03-01

  The present invention relates to compounds of Formulas I and II, wherein A 1 , A 2 , B 1 , B 2 , Q, X 1 , X 2 , Y and R 3 are defined herein, synthetic intermediates, and pharmaceutical compositions, comprising such compounds. The compounds and compositions are capable of modulating various protein kinase receptors such as Tie-2 and, therefore, influencing kinase related disease states and conditions. The compounds, for example, are capable of treating cancer caused by unregulated angiogenesis, and inflammation as well as other proliferative disorders.

  本发明涉及具有I和II式的化合物，其中在此定义了A1、A2、B1、B2、Q、X1、X2、Y和R3，合成中间体以及包括这些化合物的药物组合物。这些化合物和组合物能够调节各种蛋白激酶受体，如Tie-2，并因此影响激酶相关的疾病状态和病况。例如，这些化合物能够治疗由于未受调控的血管生成引起的癌症，以及炎症和其他增生性疾病。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DE STING
  申请人：IFM DUE INC

  公开号：WO2020243519A1

  公开（公告）日：2020-12-03

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

  这份披露涉及化学实体（例如，一种化合物或一种药用可接受的盐，和/或水合物，和/或共晶体，和/或该化合物的药物组合），其抑制（例如，对抗）干扰素基因激活剂（STING）。这些化学实体可用于治疗一种情况、疾病或紊乱，其中增加（例如，过度的）STING激活（例如，STING信号传导）导致该情况、疾病或紊乱的病理学和/或症状和/或进展（例如，癌症）在受试者（例如，人类）中。这份披露还涉及包含同样化学实体的组合物，以及使用和制备这些组合物的方法。
• CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE
  申请人：Ng Simon C.

  公开号：US20100130490A1

  公开（公告）日：2010-05-27

  Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.

  本发明公开了苯并噁唑和苯并噻唑化合物及其氧化物、酯、前药、溶剂化物和药学上可接受的盐。本发明还公开了该化合物的组合物，其可以单独使用或与至少一种额外治疗剂联合使用，并与药学上可接受的载体一起使用。该实施例可用于抑制细胞增殖，抑制肿瘤的生长和/或代谢，治疗或预防癌症，治疗或预防退变性骨疾病，如类风湿性关节炎，并/或抑制分子，如CSF 1R。
• CSF-1R, Inhibitors, Compositions, and Methods of Use
  申请人：Sutton James

  公开号：US20100261679A1

  公开（公告）日：2010-10-14

  Disclosed herein are compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof, compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

  本文公开了化合物及其氧化物、酯、前药、溶剂化物和其药学上可接受的盐，以及化合物的组合物，可以单独使用或与至少一种其他治疗剂合用，并与药学上可接受的载体一起使用，以及化合物的用途，可以单独使用或与至少一种其他治疗剂合用。这些实施例可用于抑制细胞增殖，抑制肿瘤的生长和/或代谢，治疗或预防癌症，治疗或预防类风湿性关节炎等骨骼退化性疾病，并/或抑制分子如CSF-1R。
• AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：Blench Toby Jonathan

  公开号：US20120202788A1

  公开（公告）日：2012-08-09

  Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R 1 , R 2 , R 4 and R 5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.

  提供了公式I的化合物，立体异构体，互变异构体，溶剂化物，前药和药学上可接受的盐，其中A，X，R1，R2，R4和R5在此定义，以及包括公式I的化合物和药学上可接受的载体，辅料或载体的制药组合物，使用该化合物或组合物进行治疗的方法，以及制造公式I的化合物的方法。